Anika Therapeutics (ANIK) EBIAT (2016 - 2025)
Anika Therapeutics (ANIK) has disclosed EBIAT for 16 consecutive years, with $1.1 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT fell 95.57% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.9 million, a 156.53% decrease, with the full-year FY2025 number at -$10.9 million, down 23.24% from a year prior.
- EBIAT was $1.1 million for Q4 2025 at Anika Therapeutics, up from -$3.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $25.7 million in Q4 2024 to a low of -$63.0 million in Q4 2023.
- A 5-year average of -$3.4 million and a median of -$2.9 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: skyrocketed 309.75% in 2022, then plummeted 4411.36% in 2025.
- Anika Therapeutics' EBIAT stood at -$5.8 million in 2021, then surged by 309.75% to $12.2 million in 2022, then plummeted by 618.48% to -$63.0 million in 2023, then skyrocketed by 140.78% to $25.7 million in 2024, then tumbled by 95.57% to $1.1 million in 2025.
- Per Business Quant, the three most recent readings for ANIK's EBIAT are $1.1 million (Q4 2025), -$3.2 million (Q3 2025), and -$4.0 million (Q2 2025).